Jyong Biotech Ltd. Ordinary Shares
public_traded
Jyong Biotech Ltd. Ordinary Shares is publicly traded on NASDAQ under ticker MENS.
Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stages